GlassScriptPhysician profile
Samir B Desai
NPI 1659372506
$14,219.60
in general payments reported to CMS, 2019-2025
59 companies · $4,081 in 2025
The $4,081 reported for 2025 was more than what 79% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $652 · 2020: $258 · 2021: $534 · 2022: $1,548 · 2023: $2,205 · 2024: $4,941 · 2025: $4,081.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,465 · Food and Beverage: $4,263 · Honoraria: $1,200 · Education: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,465.00 |
| Food and Beverage | $4,262.94 |
| Honoraria | $1,200.00 |
| Education | $299.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,563.05 | 2024-2025 | |
| Daiichi Sankyo INC. | $2,045.10 | 2019-2024 | Enhertu |
| Pfizer INC. | $1,589.26 | 2019-2025 | |
| Geron Corporation | $960.00 | 2025 | Rytelo |
| Avyxa Pharma, LLC | $693.05 | 2024-2025 | |
| Incyte Corporation | $595.91 | 2022-2024 | Jakafi, Monjuvi |
| Merck Sharp & Dohme LLC | $542.19 | 2019-2024 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $509.75 | 2019-2025 | Calquence, Imfinzi, Lynparza |
| Novartis Pharmaceuticals Corporation | $457.38 | 2019-2025 | |
| Amgen INC. | $456.08 | 2019-2023 | Lumakras |
| Seagen INC. | $413.33 | 2019-2023 | Padcev, Adcetris, Tukysa |
| Genentech USA, INC. | $339.94 | 2019-2025 | Venclexta, Lunsumio, Ocrevus Zunovo |
| Lilly USA, LLC | $212.97 | 2022-2024 | Verzenio |
| Janssen Biotech, INC. | $197.56 | 2020-2025 | Darzalex, Tecvayli |
| Pharmacosmos Therapeutics INC. | $181.08 | 2024 | Cosela |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samir Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.